Cosmo Pharmaceuticals NV 2021 AR2
The report highlights Cosmo Pharmaceuticals' return to profit and dividend distribution in 2021, driven by key regulatory milestones. Notably, the U.S. FDA approved GI Genius™, the first-to-market computer-aided polyp detection system using artificial intelligence, and the company successfully closed a public exchange offer to acquire Cassiopea S.p.A. Additionally, Winlevi® was launched in the U.S. by partner Sun Pharmaceutical Industries. Financially, the company reported total revenues of €65.1 million and an operating profit of €11.1 million, representing significant growth compared to the previous year.
Company: Cosmo Pharmaceuticals NV
Sector: Manufacturing
Country: Ireland
Year: 2021
Type: AR2
Pages: 159
Back to company
Cosmo Pharmaceuticals NV
Annual Report And Accounts
The report highlights Cosmo Pharmaceuticals' return to profit and dividend distribution in 2021, driven by key regulatory milestones. Notably, the U.S. FDA approved GI Genius™, the first-to-market computer-aided polyp detection system using artificial intelligence, and the company successfully closed a public exchange offer to acquire Cassiopea S.p.A. Additionally, Winlevi® was launched in the U.S. by partner Sun Pharmaceutical Industries. Financially, the company reported total revenues of €65.1 million and an operating profit of €11.1 million, representing significant growth compared to the previous year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees